RxDoctor Payments Data

Lacie Goodman

Family · Laredo, TXNPI 1477100857

Payments from drug & device makers

$4,056in general payments, 2019–2025

Across 210 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$880
  • AstraZeneca$672
  • Corium, LLC$518
  • Lilly USA, LLC$408
  • GSK$200
  • Otsuka America Pharmaceutical, Inc.$187
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$4,056100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,056 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol30$29,764
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$24,995
MounjaroTirzepatide13$16,966
RexultiBrexpiprazole12$16,264
OzempicSemaglutide12$14,938
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine38$1,648
Albuterol Sulfate HfaAlbuterol Sulfate26$769
Ondansetron OdtOndansetron12$718
NitrofurantoinNitrofurantoin Macrocrystal12$348
Pantoprazole Sodium19$280
Levothyroxine Sodium53$271
Losartan Potassium48$270
Rosuvastatin Calcium30$259
Gabapentin16$258
Lorazepam16$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$672$29,76430 claims
GSKTrelegy Ellipta$200$24,99521 claims
Lilly USA, LLCMounjaro$408$16,96613 claims
Otsuka America Pharmaceutical, Inc.Rexulti$187$16,26412 claims
Novo NordiskOzempic$128$14,93812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in Laredo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →